X

Trial Profile

Phase 1 Study to Evaluate Safety and Efficacy of APR-548 in Combination With Azacitidine for the Treatment of TP53-Mutant Myelodysplastic Syndromes

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 18 Aug 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs APR-548 (Primary) ; Azacitidine (Primary)
Indications Myelodysplastic syndromes
Focus Adverse reactions; First in man
Sponsors Aprea Therapeutics

Most Recent Events

11 Aug 2022 According to an Aprea media release, enrollment in the first dosing cohort was completed.
20 Jul 2022 Status changed from suspended to discontinued as per sponsor decision.
01 Jun 2022 Status changed from recruiting to suspended due to sponsor decision.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com